In addition, in a phase I clinical trial (NCT03182816), EGFR was targeted by non-viral piggyBac transposon system-engineered EGFR-CAR T-cell therapy in 9 patients with non-small cell lung cancer. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.